AbbVie's working toward solutions to protect its top line against Humira's inevitable decline. For now, though, its workhorse is still getting the job done, and it delivered yet another double-digit leap in Q1 to help the company beat expectations.
It's no secret that AbbVie's sales are in for a shock once generic competition starts eating away at behemoth Humira. But worry not, investors: The company will be able to shield its EPS from the hit when the time comes, one analyst believes.
Pharma analysts have different opinions on how much branded drugmakers will feel the heat from biosimilars--and when they'll feel it. But according to one Citi analyst, they're all underestimating the impact on AbbVie's top dog.
Amgen wrapped up a second successful Phase III study of its Humira knockoff, ABP501, flagging its head-to-head success in a brief thumb's up announcing that the biosimilar hit its primary and key secondary endpoints. And barring any nasty surprises the positive readout on rheumatoid arthritis should give Amgen the ammunition needed to gun for an approval in a crowded field of late-stage contenders.
AbbVie posted promising fourth-quarter earnings fueled by the strong performance of blockbuster Humira. But the company is looking beyond its top-selling med in 2015, focusing on the development of new products to bolster its bottom line as it counters generic competition to some of its key moneymakers.
With Friday's approval of all-oral hep C regimen Viekira Pak, AbbVie's got a future blockbuster on its hands. And it couldn't have arrived soon enough.
Indian drugmaker Zydus Cadila has launched a biosimilar of Humira in its home market--the first in a long line of in-development copies to threaten AbbVie's powerhouse med.
According to FirstWord Pharma, over the past four quarters, the 50 biggest-growing drugs delivered an absolute sales increase of $31 billion to their makers. While the top 5 slots on FWP 's list are filled with a who's who of recent, high-powered launches, AbbVie stalwart Humira is right up there with the new rollouts--and the list holds a few surprises lower down, too.
The market for Humira is a large one: the med raked in $11.02 billion last year to top the list of the world's best-selling drugs. So it's no surprise that biosimilar developers are going after a piece of that market--including Amgen, which released some head-to-head data last week that could help it make its regulatory case.
AbbVie may be under fire from the Federal Trade Commission for delaying AndroGel generics, but it won't have to face racketeering claims over its generics-fighting sales tactics.